NMRA Earnings Neumora Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–15 of 15
| Q1 2026 | 2026-03-31 | -0.30 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | -1.45 | 2026-03-30 | 10-K |
| Q3 2025 | 2025-09-30 | -1.10 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.75 | 2025-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.42 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -1.53 | 2026-03-30 | 10-K |
| Q3 2025 | 2024-09-30 | -1.16 | 2025-11-06 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.71 | 2025-08-06 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.34 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -3.63 | 2025-03-03 | 10-K |
| Q3 2024 | 2023-09-30 | -3.59 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -2.50 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.22 | 2024-05-07 | 10-Q |
| FY 2024 | 2022-12-31 | -4.81 | 2025-03-03 | 10-K |
| Q3 2023 | 2022-09-30 | -3.83 | 2023-11-01 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.